

# ForPatients

*by Roche*

Renal Cell Cancer (RCC) Renal Cell Carcinoma

## A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)

**Trial Status**  
Completed

**Trial Runs In**  
21 Countries

**Trial Identifier**  
NCT02420821 2014-004684-20  
WO29637

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

### ***Trial Summary:***

This multi-center, randomized, open-label study will evaluate the efficacy and safety of atezolizumab plus bevacizumab versus sunitinib in participants with inoperable, locally advanced, or metastatic RCC who have not received prior systemic active or experimental therapy, either in the adjuvant or metastatic setting.

**Hoffmann-La Roche**  
Sponsor

**Phase 3**  
Phase

---

**NCT02420821 2014-004684-20 WO29637**  
Trial Identifiers

---

### ***Eligibility Criteria:***

**Gender**  
All

**Age**  
≥18 Years

**Healthy Volunteers**  
No

---